Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

32.52
Delayed Data
As of 4:01pm ET
 +1.47 / +4.73%
Today’s Change
27.60
Today|||52-Week Range
56.44
-10.29%
Year-to-Date
Glaxo's (GSK) Shingles Candidate Phase III Data Positive
10:51am / Zacks.com - Paid Partner Content
Teva Pharmaceuticals Upgraded at Mizuho
Jun 16 / TheStreet.com - Paid Partner Content
FDA Commisoner Takes on Big Pharma
Jun 21 / TheStreet.com - Paid Partner Content
Ohio blames drugmakers for fueling opioid crisis
Jun 01 / CNNMoney.com

Today’s Trading

Previous close31.05
Today’s open31.27
Day’s range31.21 - 32.57
Volume11,002,452
Average volume (3 months)8,028,936
Market cap$31.5B
Dividend yield4.18%
Data as of 4:01pm ET, 06/22/2017

Growth & Valuation

Earnings growth (last year)-96.18%
Earnings growth (this year)-6.76%
Earnings growth (next 5 years)+0.35%
Revenue growth (last year)+12.01%
P/E ratio1,626.0
Price/Sales1.59
Price/Book1.06

Competitors

 Today’s
change
Today’s
% change
BGNEBeiGene Ltd-0.49-1.09%
OASMOasmia Pharmaceutica...+0.07+7.13%
Data as of 3:59pm ET, 06/22/2017

Financials

Next reporting dateAugust 3, 2017
EPS forecast (this quarter)$1.13
Annual revenue (last year)$22.0B
Annual profit (last year)$330.0M
Net profit margin1.50%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
President &
Chief Executive Officer
Yitzhak Peterburg
President &
CEO-Global Operations
Carlo de Notaristefani
Corporate headquarters
Petach Tikva, Hamerkaz

Forecasts